...
首页> 外文期刊>Intensive care medicine >In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.
【24h】

In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

机译:氟罗沙星对从医院感染患者中分离出来的多重耐药革兰氏阴性杆菌的体外活性。

获取原文
获取原文并翻译 | 示例
           

摘要

In order to evaluate the in vitro activity of fleroxacin against nosocomial gram-negative organisms, 263 multiresistant gram-negative bacilli (203 Enterobacteriaceae and 60 non-fermenting gram-negative bacilli) were isolated from adult patients with nosocomial infections. The different patterns of resistance to eight different antimicrobial agents (ampicillin, carbenicillin, piperacillin, cephalothin, cefamandole, ceftazidime, gentamicin and amikacin) were determined by minimum inhibitory concentration (MIC), using the agar dilution method. The most prevalent multiresistant species isolated were Klebsiella pneumoniae (28.9%), Escherichia coli (24%) and Pseudomonas aeruginosa (12.2%). All these bacterial strains showed three to five resistance patterns to at least three different antibiotics. Resistance to ceftazidime was observed in at least one of the resistance patterns of isolated bacteria. The activity of fleroxacin against multiresistant enteric bacteria was excellent; these strains showed a susceptibility of 79-100%. The susceptibility of P. aeruginosa to antipseudomonal agents was low; however, the activity of fleroxacin against these strains was higher than 60% (MIC < or = 2 microg/ ml), broadly comparable with ciprofloxacin. The resistance to fluoroquinolones detected in this study was no cause for alarm (3%). Consequently, fleroxacin maintains a remarkable activity against Enterobacteriaceae and remains highly active against other gram-negative bacilli. Nevertheless, actions directed at preventing or limiting resistance will be crucial to maintain the viability of fluoroquinolones as important therapeutic agents.
机译:为了评估氟罗沙星对医院内革兰氏阴性菌的体外活性,从成年医院感染的成人患者中分离出了263株多重耐药的革兰氏阴性杆菌(203个肠杆菌科细菌和60个非发酵革兰氏阴性杆菌)。使用琼脂稀释法通过最小抑菌浓度(MIC)确定对八种不同抗菌剂(氨苄青霉素,羧苄青霉素,哌拉西林,头孢菌素,头孢曼多尔,头孢他啶,庆大霉素和丁胺卡那霉素)的不同抗药性。分离出的最普遍的多重耐药菌是肺炎克雷伯菌(28.9%),大肠杆菌(24%)和铜绿假单胞菌(12.2%)。所有这些细菌菌株对至少三种不同的抗生素表现出三至五种抗药性。在分离的细菌的至少一种耐药模式中观察到对头孢他啶的耐药。氟罗沙星对多重耐药肠细菌的活性极佳;这些菌株显示出79-100%的敏感性。铜绿假单胞菌对抗假单胞菌药的敏感性低。但是,氟罗沙星对这些菌株的活性高于60%(MIC <或= 2 microg / ml),与环丙沙星大致相当。在这项研究中检测到的对氟喹诺酮类药物的耐药性没有引起警报的原因(3%)。因此,氟罗沙星对肠杆菌科具有显着的活性,对其他革兰氏阴性杆菌也具有很高的活性。然而,针对预防或限制耐药性的作用对于维持氟喹诺酮类作为重要治疗剂的生存力至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号